Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Meda Acquires Roche Products | Contract Pharma

What are you searching for?

Sign in
Breaking News

Meda Acquires Roche Products

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Meda has reached an agreement with Roche to acquire four of its pharmaceutical products, strengthening its key therapy areas: cardiology, CNS and pain/inflammation. Meda acquired worldwide rights to the products, with the major markets including Germany, Spain, Switzerland, the U.S. and France. The purchase price is approximately $180 million, equivalent to about two times annual sales.
   
The acquired products are: Marcoumar, an anticoagulant; Torem, an antihypertensive; Tilcotil, a NSAID drug for the treatment of painful inflammatory and degenerative disorders such as rheumatoid arthritis and osteoarthritis; and Aurorix, a MAO-A inhibitor and antidepressant. The acquisition is dependent on antitrust approval.
  
“I’m glad that we could reach this deal with Roche. The products strengthen our marketing affiliates’ position in key therapy areas. Therefore, good market synergies are expected,” said Anders Lonner, chief executive officer of Meda.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters